Treatment with Vyepti Significantly Reduced Monthly Migraine Days in a Predominantly Asian Population with Chronic Migraine

Treatment with Vyepti (eptinezumab-jjmr; Lundbeck, Copenhagen, Denmark) was shown to significantly reduce monthly migraine days (MMDs) compared with placebo in adults with chronic migraine, according to new findings from the phase 3 SUNRISE clinical trial (NCT04921384) published in Cephalagia. The study's primary end point was met, with individuals treated with Vyepti showing significantly greater reductions in MMDs over weeks 1 through 12 vs placebo, with onset of benefit beginning the day after infusion.

In SUNRISE, a randomized, double-blind, placebo-controlled trial, 978 participants with chronic migraine were randomized 1:1:1 to receive treatment with Vyepti 100 mg, Vyepti 300 mg, or placebo via IV infusion. Participants recorded headache characteristics in an electronic diary throughout the 12-week double-blind period. The full-analysis set included 972 participants.

The study met its primary end point, with a mean change in MMDs from baseline to week 12 of -7.2 for those treated with Vyepti 100 mg, -7.5 for those treated with Vyepti 300 mg, and -4.8 for those treated with placebo. There was a between-group difference of -2.4 MMDs for Vyepti 100 mg vs placebo and -2.7 for Vyepti 300 mg vs placebo, both with a P<.001.

Other key findings for weeks 1 to 12 include the following:

• Compared with placebo, both dose levels of Vyepti showed an odds ratio (OR) >2 in terms of ≥50% MMD response (P<.0001) and ≥75% MMD response (P<.0001).
• The percentage of participants with migraine on day 1 after infusion was 41.0% for the Vyepti 100 mg group, 38.8% for the Vyepti 300 mg, and 50.9% for placebo.
• There were similar safety outcomes across treatment groups, with treatment emergent adverse events (TEAEs) occurring in 37.6% of participants in the Vyepti 100 mg group, 32.2% in the Vyepti 300 mg group, and 33.5% in the placebo group.

Source: Yu S, Matsumori Y, Kim BK, et al. Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. Cephalalgia. 2025;45(10):3331024251386095. doi:10.1177/03331024251386095